Online citations, reference lists, and bibliographies.
← Back to Search

Treatment Of Non-small-cell Lung Cancer With Erlotinib Or Gefitinib.

V. Cataldo, D. Gibbons, R. Pérez-Soler, A. Quintás-Cardama
Published 2011 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
A 64-year-old woman receives the diagnosis of metastatic non-small-cell lung cancer (NSCLC), which has progressed during treatment with carboplatin, paclitaxel, and bevacizumab. Erlotinib therapy is recommended.
This paper references
10.1158/1078-0432.CCR-07-0560
Prospective Assessment of Discontinuation and Reinitiation of Erlotinib or Gefitinib in Patients with Acquired Resistance to Erlotinib or Gefitinib Followed by the Addition of Everolimus
G. Riely (2007)
10.1016/S0092-8674(00)00114-8
Cell Signaling by Receptor Tyrosine Kinases
J. Schlessinger (2000)
10.1200/JCO.2009.27.18_SUPPL.LBA8002
A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC).
V. Miller (2009)
10.1056/NEJMOA040938
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
T. Lynch (2004)
10.1016/J.YPDI.2011.02.005
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
L. Tanoue (2011)
10.1056/NEJMOA044238
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.
S. Kobayashi (2005)
10.1016/S0140-6736(08)61758-4
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
E. Kim (2008)
10.1200/JCO.2005.02.840
TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.
R. Herbst (2005)
10.1016/S0092-8674(00)81683-9
The Hallmarks of Cancer
D. Hanahan (2000)
prospective randomized trial of do ce - taxel versus best supportive care in patients with non - small - cell lung cancer previously treated with platinum - based chemothera
N Hanna (2000)
Can - cer Statistics , 2010
JH Schiller
10.3322/caac.20073
Cancer Statistics, 2010
A. Jemal (2010)
10.1200/JCO.2004.07.215
Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.
R. Herbst (2004)
10.1097/JTO.0b013e31818396a4
Phase I Trial of Erlotinib-Based Multimodality Therapy for Inoperable Stage III Non-small Cell Lung Cancer
N. Choong (2008)
10.1016/j.cell.2010.06.011
Cell Signaling by Receptor Tyrosine Kinases
M. Lemmon (2010)
10.1126/SCIENCE.1099314
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
J. Paez (2004)
10.1016/S1040-1741(08)79219-4
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
N. Hanna (2008)
10.1200/JCO.2007.13.1128
Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity.
C. Rudin (2008)
10.1158/1078-0432.CCR-06-0462
Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib
D. Jackman (2006)
10.1016/S1470-2045(09)70364-X
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.
T. Mitsudomi (2010)
10.1634/THEONCOLOGIST.12-3-325
Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
L. Sequist (2007)
10.1097/JTO.0b013e3181eba657
Chemoradiotherapy and Gefitinib in Stage III Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor and KRAS Mutation Analysis: Cancer and Leukemia Group B (CALEB) 30106, a CALGB-Stratified Phase II Trial
N. Ready (2010)
10.1056/NEJMra0802714
Lung cancer.
R. Herbst (2008)
10.1200/JCO.2000.18.10.2095
Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.
F. Shepherd (2000)
10.1016/S0140-6736(05)67625-8
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
N. Thatcher (2005)
10.1056/NEJMOA011954
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.
J. Schiller (2002)
10.1038/35052073
Untangling the ErbB signalling network
Y. Yarden (2001)
Epidermal growth factorThe New England Journal of Medicine Downloaded from nejm.org by RONALD
DS Salomon (2011)
10.1016/J.CGH.2007.04.014
Fulminant hepatic failure secondary to erlotinib.
Weitian Liu (2007)
10.1200/JCO.2007.15.2280
Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21.
P. Wheatley-Price (2008)
Rash severity is predictive of increased survival with erlotinib HCl
GM Clark (2003)
10.1016/S8756-3452(09)79377-6
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
L. Tanoue (2010)
10.1016/1040-8428(94)00144-I
Epidermal growth factor-related peptides and their receptors in human malignancies.
D. Salomon (1995)
10.1038/sj.onc.1204082
The EGF receptor family as targets for cancer therapy
J. Mendelsohn (2000)
10.1073/pnas.0710370104
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
J. Bean (2007)
10.1158/1078-0432.CCR-05-2235
Effects of Smoking on the Pharmacokinetics of Erlotinib
M. Hamilton (2006)
10.1158/1078-0432.CCR-06-0658
Update on Epidermal Growth Factor Receptor Mutations in Non–Small Cell Lung Cancer
G. Riely (2006)
10.1200/JCO.2007.11.6210
Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101.
A. Miller (2007)
10.1126/SCIENCE.1101637
Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways
R. Sordella (2004)
10.1200/JCO.2003.10.038
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].
M. Fukuoka (2003)
10.1371/journal.pmed.0020073
Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
W. Pao (2005)
10.1016/J.CRITREVONC.2007.10.004
Clinical significance and treatment of skin rash from erlotinib in non-small cell lung cancer patients: results of an Experts Panel Meeting.
C. Gridelli (2008)
10.1159/000112795
Impact and Management of Skin Toxicity Associated with Anti-Epidermal Growth Factor Receptor Therapy: Survey Results
S. Boone (2007)
10.1038/264026A0
Transformation by murine and feline sarcoma viruses specifically blocks binding of epidermal growth factor to cells
G. Todaro (1976)
10.1158/1078-0432.CCR-07-0088
Differential Metabolism of Gefitinib and Erlotinib by Human Cytochrome P450 Enzymes
J. Li (2007)
10.1200/JCO.2005.04.057
Practical management of patients with non-small-cell lung cancer treated with gefitinib.
Neelam T Shah (2005)
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
L. Huan (2010)
10.1200/jco.2009.27.18s.lba8002
A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC).
V. Miller (2009)
10.1158/1078-0432.CCR-06-1570
Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors
M. Balak (2006)
10.1200/JCO.2004.08.163
Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.
N. Hanna (2004)
10.1016/j.cell.2006.05.013
An Allosteric Mechanism for Activation of the Kinase Domain of Epidermal Growth Factor Receptor
X. Zhang (2006)
National Institutes of Health , National Cancer Institute Web site
GJ Todaro
10.1056/NEJMOA061884
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.
A. Sandler (2006)
Gefitinib in combination with paclitaxel and carboplatin in advanced nonsmall-cell lung cancer: a phase III trial
RS Herbst (2004)
Gefitinib in combination with gemcitabine and cisplatin in advanced nonsmall-cell lung cancer: a phase III trial
G Giaccone (2004)
10.1016/J.CTRV.2004.08.002
Gefitinib does not improve survival when combined with paclitaxel and carboplatin chemotherapy in people with advanced non-small-cell lung cancer.
W. Evans (2004)
Tarceva ( erlotinib ) package insert Iressa ( gefitinib ) package insert
CM Rudin
10.1200/JCO.2004.08.001
Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.
G. Giaccone (2004)
10.1158/1078-0432.CCR-06-2610
Correlation between Development of Rash and Efficacy in Patients Treated with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib in Two Large Phase III Studies
B. Wacker (2007)
10.1016/S8756-3452(08)70369-4
Erlotinib in Previously Treated Non-Small-Cell Lung Cancer
L. Tanoue (2007)



This paper is referenced by
10.1007/s12022-012-9222-y
Biomarkers of Parathyroid Carcinoma
B. Erovic (2012)
10.2217/LMT.13.42
Gefitinib: re-emerging from the shadows
Petra Moreno Martín (2013)
10.4103/0974-620X.137159
Rapid regression of choroidal metastasis from lung cancer using erlotinib (Tarceva)
Xuemei Ye (2014)
10.1186/1471-2407-11-423
Efficacy of epidermal growth factor receptor targeting in advanced chordoma: case report and literature review
S. Launay (2011)
10.1016/j.lungcan.2013.11.016
Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: a systematic review and meta-analysis of clinical trials.
L. Shi (2014)
10.1007/s00280-012-1889-8
A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors
G. Vlahovic (2012)
10.1007/s00330-014-3579-x
Prognostic potential of initial CT changes for progression-free survival in gefitinib-treated patients with advanced adenocarcinoma of the lung: a preliminary analysis
Y. Wu (2014)
Long noncoding RNA PVT-1 predicts poor patient prognosis in non-small cell lung cancer
W. Wang (2016)
10.3892/ijo.2019.4934
8‑Gingerol regulates colorectal cancer cell proliferation and migration through the EGFR/STAT/ERK pathway.
Sumin Hu (2019)
Genre Analysis of Applied linguistics Research Article Introductions Published in International and Iranian Local Journals
S. Ebrahimi (2018)
10.5772/25633
Inflammation, Aging and Cancer: Friend or Foe?
M. Khatami (2012)
10.1038/bjc.2013.728
PA28gamma emerges as a novel functional target of tumour suppressor microRNA-7 in non-small-cell lung cancer
S. Xiong (2014)
10.1016/j.soncn.2012.03.004
Biomarkers as molecular targets of drug interventions.
Judith J. Smith (2012)
10.1158/1078-0432.CCR-13-2695
Importance of EGFR/ERCC1 Interaction Following Radiation-Induced DNA Damage
G. Liccardi (2014)
10.1371/journal.ppat.1004128
Hepatitis C Virus Cell-Cell Transmission and Resistance to Direct-Acting Antiviral Agents
Fei Xiao (2014)
10.1038/s41467-019-11490-5
PTPσ inhibitors promote hematopoietic stem cell regeneration
Yurun Zhang (2019)
10.1111/j.1365-2559.2012.04245.x
Consistent mutation status within histologically heterogeneous lung cancer lesions
Johanna S. M. Mattsson (2012)
10.1093/jjco/hyr079
Phase II study of erlotinib as third-line monotherapy in patients with advanced non-small-cell lung cancer without epidermal growth factor receptor mutations.
S. Matsuura (2011)
10.3390/ijms150813768
Small-Molecule Inhibitors of the Receptor Tyrosine Kinases: Promising Tools for Targeted Cancer Therapies
M. Hojjat-Farsangi (2014)
10.1038/srep30346
Co-targeting EGFR and survivin with a bivalent aptamer-dual siRNA chimera effectively suppresses prostate cancer
H. Liu (2016)
Cancer Therapy : Preclinical ImportanceofEGFR / ERCC 1 InteractionFollowingRadiation-Induced DNA Damage
G. Liccardi (2014)
10.1007/s12032-013-0810-6
Mutation abundance affects the efficacy of EGFR tyrosine kinase inhibitor readministration in non-small-cell lung cancer with acquired resistance
Z. Zhao (2013)
10.1310/hpj4705-401
Recent Publications on Medications and Pharmacy
Flint Russett (2011)
10.1310/hpj4605-374
Recent Publications on Medications and Pharmacy
Flint Russett (2011)
10.1038/onc.2012.154
Met signaling regulates growth, repopulating potential and basal cell-fate commitment of mammary luminal progenitors: implications for basal-like breast cancer
S. Gastaldi (2013)
10.1158/1940-6207.CAPR-11-0143
Cotargeting Cyclin D1 Starts a New Chapter in Lung Cancer Prevention and Therapy
E. Kim (2011)
10.1097/JTO.0b013e31824cc34a
Erlotinib in symptomatic brain metastases from a lung adenocarcinoma with a sensitizing EGFR mutation.
L. H. de Lima Araújo (2012)
10.3760/cma.j.issn.0366-6999.20130578
Serum cytokine levels in patients with advanced non‐small cell lung cancer: correlation with clinical outcome of erlotinib treatment
Yong-sheng Wang (2013)
10.1186/s12943-015-0366-5
Synergistic anti-tumor effect of combined inhibition of EGFR and JAK/STAT3 pathways in human ovarian cancer
W. Wen (2015)
Preclinical Development SKLB 1206 , a Novel Orally Available Multikinase Inhibitor Targeting EGFR Activating and T 790 M Mutants , ErbB 2 , ErbB 4 , and VEGFR 2 , Displays Potent Antitumor Activity Both In Vitro and In Vivo
Youli Pan (2012)
10.1016/j.microc.2019.104588
The N,S co-doped carbon dots with excellent luminescent properties from green tea leaf residue and its sensing of gefitinib
Zhixiong Hu (2020)
10.3389/fonc.2016.00045
Current Management Strategies in Breast Cancer by Targeting Key Altered Molecular Players
S. Ali (2016)
See more
Semantic Scholar Logo Some data provided by SemanticScholar